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 Resumo 
 A perfusão contínua de suspensão em gel de levodopa/
carbidopa (Duodopa ® ) para o intestino delgado através 
de sonda jejunal, via gastrostomia percutânea endoscó-
pica, representa um novo método de tratamento na 
Doença de Parkinson avançada. Nos últimos anos têm 
sido descritas algumas complicações graves, algumas das 
quais relacionadas com a formação de fitobezoares na 
ponta “pigtail” do catéter. Apresentamos o caso de um 
doente com doença de Parkinson tratado com sistema de 
infusão Duodopa complicado por fistulização da sonda 
jejunal para o cólon. Sugere-se uma estratégia terapêuti-
ca para esta complicação, não descrita na literatura até à 
data.  © 2017 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel
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 Abstract 
 The continuous delivery of a levodopa/carbidopa gel sus-
pension (Duodopa ® ) into the small bowel through a jejunal 
tube inserted via percutaneous endoscopic gastrostomy 
represents a new treatment method in advanced Parkinson 
disease. Some severe device-related complications have 
been described in the last few years. Some of them are as-
sociated with phytobezoar formation at the pigtail of the 
catheter. We present the case of a Parkinson disease patient 
treated with the Duodopa infusion system complicated by 
jejunal tube fistulization into the colon. We suggest a pos-
sible treatment strategy for this complication, which has not 
been described in the literature to date. 
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 The continuous delivery of levodopa/carbidopa gel 
(Duodopa ® ) to the small intestine through a jejunal tube 
in some patients with advanced Parkinson disease (PD) 
enables less variability in levodopa concentrations, result-
ing in fewer motor fluctuations and dyskinesia compared 
with oral administration  [1] . The drug-containing gel is 
steadily pumped into the upper jejunum through an ex-
tension tube inserted through a percutaneous endoscop-
ic gastrostomy (J-PEG)  [2, 3] .
 We describe a serious gastrointestinal complication 
associated with the Duodopa infusion system.
 Case Report 
 A 56-year-old woman with a 26-year history of akinetic rigid 
PD was proposed Duodopa therapy due to motor symptoms dur-
ing the previous 7 years, such as fluctuations and dyskinesias, de-
spite optimized oral levodopa/carbidopa treatment. The patient 
underwent J-PEG for duodenal levodopa/carbidopa gel infusion 
with a great benefit on parkinsonian symptoms. Two and a half 
years later, the patient reported worsening of motor symptoms 
despite increased daily dosage of Duodopa, warranting supple-
mentation with oral levodopa/carbidopa.
 After 3 months, the patient was admitted to our endoscopic 
department for elective J-PEG substitution. Gastroscopy showed 
an ulceration area at the transition from the second to the third 
duodenal portion wall caused by the jejunal tube ( Fig. 1 ). Contrast 
injection showed the tip of the catheter at the right lower quadrant 
of the abdomen, apparently in the ascending colon ( Fig. 2 a). Re-
moval of the jejunal device was impossible because it was blocked 
when pulled out manually.
 The patient was submitted to a contrast-enhanced CT scan 
that revealed an intraparietal jejunal tube in the third duodenal 
portion, with multiple downstream enteroenteric fistulae. The 
tip of the catheter was placed in the hepatic angle where an ir-
regular parietal thickening was observed ( Fig. 2 b). Colonoscopy 
showed the tip of the jejunal tube crossing the cecal wall later-
ally to the ileocecal valve, entrapped in a phytobezoar ( Fig. 3 ). It 
was possible to pull the tip of the jejunal tube with an endoscop-
ic snare to the transverse colon, but at this level, the resistance 
increased considerably due to proximal fixation. After opening 
the snare, the tip of the catheter spontaneously returned to the 
ascending colon.
 After multidisciplinary discussion (surgery, radiology, neurol-
ogy, and gastroenterology) regarding the complexity of a surgical 
solution and the stability of the patient’s clinical status, a wait-and-
see attitude was decided. The patient was maintained on oral le-
vodopa/carbidopa. PEG was removed and the proximal tip of the 
jejunal tube was cut. Two days after this procedure, complete anal 
exteriorization of the jejunal tube spontaneously occurred, with-
out any clinical adverse events.
 Discussion 
 Duodopa is a very effective therapy, enabling continu-
ous 24-hour dopaminergic stimulation; therefore, it pro-
vides stability in motor and nonmotor symptoms as com-
pared to conventional treatment  [4] .
 Over the last few years, some severe late gastrointesti-
nal complications in patients with Duodopa infusion 
have been described, many of them related to phytobe-
zoar formation at the tip of the jejunal tube. Klostermann 
et al.  [5]  reviewed the medical reports of 52 patients with 
levodopa/carbidopa gel intestinal infusion. Two patients 
with mechanical ileus, induced by fiber-rich residuals 
around the extension tube causing intestinal obstruction, 
were identified  [5] . Similarly, Schrader et al.  [6] described 
2 cases of phytobezoar formation at the pigtail tip of the 
jejunal tube, inducing the formation of gastric and jejunal 
pressure ulcers and jejunal obstruction at the phytobe-
zoar level in 1 of the patients.
 Fistulization has also been described as a J-PEG-relat-
ed complication. Bianco et al.  [7]  reported a case of a J-
PEG jejunal tube penetrating through the gastric mucosa, 
causing fistulization of 3 intestinal loops and jejunal wall 
perforation. A phytobezoar covering the catheter was 
seen at the perforation site. The patient required intesti-
nal resection and died from postoperative complications 
 [7] . Olivares et al.  [8] reported the case of a patient with 
mechanical small bowel obstruction. The investigation 
revealed multiple ulcerations in the duodenum and jeju-
num and the fistulization of the tube through the jejunal 
wall into the mesenteric root. The plain abdominal X-ray 
showed the distal end of the catheter at the ileum level. 
After an endoscopic attempt to remove the tube, the pa-
 Fig. 1. Endoscopy showing the catheter inducing an ulceration be-
tween the second and third duodenal portions. 
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tient showed signs of pneumoperitoneum. Immediate 
surgery was required which showed multiple areas of in-
testinal perforation. The patient died after 2 days  [8] . The 
same authors described a case of a large antro-duodenal 
ulcer due to the pressure of the jejunal tube. After an en-
doscopic removal attempt, severe hemorrhage and hemo-
dynamic instability were noted. The pigtail ending of the 
tube was clogged with a bezoar  [8] .
 Our case illustrates a very serious phytobezoar-related 
complication of the Duodopa infusion system. Since PEG 
tubes are frequently used to feed patients who cannot eat 
solid food, they do not usually predispose to phytobe-
zoars. However, when using J-PEG tubes for intrajejunal 
Duodopa infusion, patients may ingest a large portion of 
indigestible fibers and form phytobezoars at the pigtail of 
the J-PEG tube. Peristaltic movements can propel the be-
zoar, stretching the J-PEG tube. When the J-PEG tube is 
stretched tightly, it may carve in the mucosa and cause 
pressure ulcers  [6] . Schrader et al.  [6]  suggest a low-fiber 
diet as the probably best way to avoid bezoar formation.
 The loss of response with symptom worsening, as in 
our patient, should alert clinicians to some potentially se-
vere complications (such as tube obstruction, knotting, or 
fistulization beyond the small bowel) and should suggest 
prompt endoscopic examination. It is advisable to substi-
tute the jejunal tube every 12 months to avoid late J-PEG 
tube complications.
 Unlike the fatal reports published in the literature, our 
patient spontaneously expelled the jejunal tube without 
any adverse events. A wait-and-see attitude should be 
considered as an option when these complications occur.
 Statement of Ethics 
 This study did not require informed consent or review/approv-
al by the appropriate ethics committee.
 Disclosure Statement 
 The authors have no conflicts of interest to disclose.
 
a b
 Fig. 2.  a Fluoroscopy image showing con-
trast injection into the transverse colon and 
the tip of the catheter at the hepatic angle. 
 b CT scan portraying enteroenteric and en-
terocecal fistulae. 
 Fig. 3. Colonoscopy illustrating the tip of the jejunal tube, crossing 
the cecal wall lateral to the ileocecal valve. The tip of the jejunal 
tube was entrapped in a phytobezoar. 
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